Roivant Sciences Ltd.: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 12, 2024 and accepted by EDGAR at Nov 12, 2024, 07:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $4.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-04-01 to 2024-09-30 | $12.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $143.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-04-01 to 2024-09-30 | $263.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$341.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-04-01 to 2024-09-30 | −$443.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $12.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-04-01 to 2024-09-30 | $24.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$230.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-04-01 to 2024-09-30 | −$134.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | −$0.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-04-01 to 2024-09-30 | −$0.18 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.31 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-04-01 to 2024-09-30 | −$0.18 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 735,470,796 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-04-01 to 2024-09-30 | 735,642,721 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-04-01 to 2024-09-30 | −$459.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-04-01 to 2024-09-30 | $2.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2024-04-01 to 2024-09-30 | $754.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-09-30 | $1.96bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $5.80bn | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $6.21bn | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $556.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-09-30 | $626.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-09-30 | $5.15bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-24-046019. Last ingested by Listed: Nov 9, 2026, 17:41 ET. Listed shows no prices and gives no investment advice.